跳至主要内容
临床试验/CTRI/2021/03/032208
CTRI/2021/03/032208已完成未知

Clinical validation of safety and efficacy of PIHF in improving immunity. - Nil

aturedge Beverages Pvt Ltd0 个研究点目标入组 30 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Male and female subjects aged 18 to 60 years (both the ages inclusive)
  • Ready to provide written informed consent
  • With or without propensity of seasonal cough, cold and allergic episodes
  • Willing to come for the follow-up visits for evaluation

排除标准

  • Presence of clinically significant known abnormal laboratory, ECG or X-ray findings during screening.
  • Patients with known uncontrolled diabetes mellitus (DM) HbA1C more than 7.5, hypertension (HT), symptomatic congestive heart failure (CHF), unstable angina pectoris, myocardial infarction (MI)
  • Subjects with current medical history of any major illness such as cancer, heart disease, COPD, Asthma etc. in the past
  • Patients participated in another clinical drug trial within 3 months before recruitment in this trial
  • Any other medical condition that in the Investigators opinion would preclude patient participation
  • Pregnant and breast feeding women and women of child bearing age refusing to use contraceptive measures
  • Immunologically compromised individuals
  • Subjects with past history of addiction abuse and rehabilitation
  • Subject consuming more than 1 cigarette per day

研究者

发起方
aturedge Beverages Pvt Ltd

相似试验